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Bioengineered kidney tubules 
efficiently excrete uremic toxins
J. Jansen1,2,3,4,*, M. Fedecostante1,2,3,4,*, M. J. Wilmer1, J. G. Peters1, U. M. Kreuser1,  
P. H. van den Broek1, R. A. Mensink5, T. J. Boltje5, D. Stamatialis6, J. F. Wetzels7,  
L. P. van den Heuvel3,8, J. G. Hoenderop2 & R. Masereeuw4
The development of a biotechnological platform for the removal of waste products (e.g. uremic 
toxins), often bound to proteins in plasma, is a prerequisite to improve current treatment modalities 
for patients suffering from end stage renal disease (ESRD). Here, we present a newly designed 
bioengineered renal tubule capable of active uremic toxin secretion through the concerted action of 
essential renal transporters, viz. organic anion transporter-1 (OAT1), breast cancer resistance protein 
(BCRP) and multidrug resistance protein-4 (MRP4). Three-dimensional cell monolayer formation 
of human conditionally immortalized proximal tubule epithelial cells (ciPTEC) on biofunctionalized 
hollow fibers with maintained barrier function was demonstrated. Using a tailor made flow system, the 
secretory clearance of human serum albumin-bound uremic toxins, indoxyl sulfate and kynurenic acid, 
as well as albumin reabsorption across the renal tubule was confirmed. These functional bioengineered 
renal tubules are promising entities in renal replacement therapies and regenerative medicine, as well 
as in drug development programs.
Chronic renal failure (CRF) is a severe health problem with a high morbidity and mortality rate as adequate 
therapy is currently not available. Impaired renal function results in the accumulation of various endogenous 
uremic metabolites (i.e. uremic toxins), which are associated with a broad range of pathologies that constitute 
the uremic syndrome1–3. The preferred treatment option for end-stage renal disease (ESRD) is organ transplan-
tation, however, the worldwide organ shortage is profound and many patients experience graft failure4,5. Chronic 
dialysis (hemodialysis or peritioneal dialysis) is currently the best alternative treatment option, which is widely 
applied and efficient in removal of small water-soluble and middle molecular weight molecules, but it insuffi-
ciently removes larger and protein-bound uremic toxins6,7. The latter class comprises end-metabolites that orig-
inate from dietary breakdown amino acids, such as tyrosine, phenylalanine and l-tryptophan, for which their 
pathological role in the progression of the uremic syndrome has gained substantial interest in the last decade6.
The majority of dietary protein derived l-tryptophan is metabolized to l-kynurenine, which in turn can be 
converted into kynurenic acid. Accumulation of kynurenic acid was found to correlate with several symptoms 
of uremia, including neurological disturbances, lipid metabolism disorder and anemia8. Tryptophan can also 
be metabolized by intestinal bacteria into indoles, which are processed further in the liver into indoxyl sul-
fate, indole-3 acetic acid and indoxyl-β-D-glucuronide9. Indoxyl sulfate as well as the tyrosine end-metabolites 
p-cresyl sulfate and p-cresyl glucuronide are associated with cardiovascular disease development via the activa-
tion of leukocytes, reactive oxygen species (ROS) production and their interaction with the vascular endothe-
lium10–12. Furthermore, the p-cresol derivates demonstrated cytotoxicity and a pro-inflammatory response in 
renal epithelial cells13, possibly contributing to CRF progression. Also, drug disposition is altered in patients with 
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CRF, not only because of diminished kidney function but also due to a direct inhibition of drug transporters and 
drug-metabolism enzymes by uremic toxins14,15.
The residual renal function in ESRD patients is not only associated with the remaining glomerular filtration 
capacity, but also the ability of the proximal nephron segment to actively secrete protein-bound uremic toxins 
into the pro-urine16,17. To this end, proximal tubule epithelial cells (PTEC) are equipped with a broad range of 
transport proteins that accept a wide range of xenobiotics, including exogenous compounds such as drugs, and 
endogenous (waste) metabolites. At the basolateral membrane the organic anion transporters 1 (OAT1; SLC22A6) 
and −3 (OAT3; SLC22A8) of the solute carrier family (SLC), are highly efficient in the uptake of the anionic ure-
mic toxins such as the l-tryptophan, tyrosine and phenylalanine end-metabolites, shifting their protein binding 
to the free fraction8,18,19. At the luminal side, the ATP binding cassette (ABC) transporters breast cancer resistance 
protein (BCRP; ABCG2) and the multidrug resistance-associated proteins 2 and −4 (MRP2/4; ABCC2/4) are 
involved in their urinary secretion20.
As the removal of protein-bound uremic toxins via PTEC is associated with better patients survival, the engi-
neering of a bioartificial kidney (BAK) containing PTEC cultured on hollow fiber membranes (HFM) could be 
a promising platform to advance uremic toxin clearance. This was the focus of the current study using human 
conditionally immortalized PTEC (ciPTEC), expressing endogenously a broad range of functional transporters 
associated with uremic toxin handling21,22. Recently, complemented with OAT1 and −3 that are generally lost 
in PTEC upon culturing23. The cells carry the temperature-sensitive mutant U19tsA58 of SV40 large T antigen 
(SV40T) and the essential catalytic subunit of human telomerase (hTERT), allowing the cells to proliferate at 
the permissive low temperature of 33 °C and differentiate to mature PTEC at 37 °C, and maintenance of tel-
omere length preventing replicative senescence, respectively. This resulted in stable cell lines that could be main-
tained over a long period of time, and a valuable tool for studying renal clearance processes as required for BAK 
engineering.
In the present study, we demonstrate the development of functional bioengineered renal tubules that effi-
ciently clear protein-bound anionic uremic toxins. First, the essential role of in- and efflux transporters in the 
removal of uremic toxins was studied in flat monolayers. Subsequently, three dimensional, polarized, ciPTEC 
monolayers on biofunctionalized polyethersulfone hollow fiber membranes were developed. Finally, as a cru-
cial next step in BAK engineering, the secretory clearance of human serum albumin-bound indoxyl sulfate and 
kynurenic acid was confirmed, as well as albumin reabsorption.
Results
Uremic toxins inhibit OAT1 and OAT3 activity at clinically relevant concentrations. To evaluate 
the role of uptake transporters in uremic toxin handling, a panel of eight anionic uremic toxins was selected to 
study their affinity to inhibit OAT1- and OAT3-mediated uptake in ciPTEC. These toxins were selected based on 
their structure and potential PTEC-mediated urinary secretion, and their previously suggested association with 
complications of CRF13–15,19. The OAT1 and −3 model substrate fluorescein was used to evaluate transporter 
function23. A concentration-dependent inhibition of fluorescein uptake was shown for all anionic uremic toxins 
tested (Fig. 1), with most potent interactions found for kynurenic acid and hippuric acid (Fig. 1d,f, resp. and 
Table 1). The inhibitory potencies of the toxins, as reflected by their IC50 values (Table 1), were higher for OAT1 
compared to OAT3, except for p-cresylglucuronide.
The renal excretion of indoxyl sulfate and kynurenic acid is OAT1-, BCRP- and MRP4-mediated. 
Indoxyl sulfate and kynurenic acid were selected for further studies using the ciPTEC-OAT1 model, as both 
showed a strong OAT1-mediated inhibition and have been associated severely with ESRD progression and its 
related complications8,15,24,25. Next to their inhibitory potency, we studied active PTEC transport processes. A 
dose-dependent uptake of indoxyl sulfate by ciPTEC-OAT1 monolayers was observed (Fig. 2a, 1.2 ± 0.1 and 
6.7 ± 0.9 pmol.min−1.cm−2, at 3 and 30 μM respectively), which was sensitive to probenecid inhibition (by 83 ± 6 
and 63 ± 5% for 3 and 30 μM, respectively; p < 0.001), a classical OAT inhibitor26. Indoxyl sulfate uptake was also 
inhibited by kynurenic acid (100 μM; by 64 ± 13 and 61 ± 5% for 3 and 30 μM, respectively; p < 0.001), while 
kynurenic acid uptake by OAT1 was not significantly affected by indoxyl sulfate (100 μM), most likely due to a 
higher affinity of kynurenic acid for the transporter than indoxyl sulfate8. But dose-dependent kynurenic acid 
uptake (Fig. 2b, 2.7 ± 0.3 and 5.9 ± 0.5 pmol.min−1.cm−2 for 3 and 30 μM, respectively) in ciPTEC-OAT1 was also 
sensitive to probenecid (53 ± 10 and 52 ± 12% inhibition, respectively; p < 0.05).
Using a vesicular transport assay for evaluating the activities of BCRP and MRP414, Mutsaers et al. showed 
previously that indoxyl sulfate and kynurenic acid are potent inhibitors of both efflux pumps. Moreover, the 
intrinsic PTEC toxicity of the uremic toxins was demonstrated by their ability to reduce renal metabolic capacity 
and to increase free radical production in proximal tubule epithelial cells15,19. Here, the role of BCRP and MRP4 
in indoxyl sulfate and kynurenic acid detoxification was studied further using a cell viability assay (Fig. 2c,d). 
CiPTEC showed to be slightly more sensitive to both uremic toxins when BCRP and MRP4 were inhibited by 
KO143 and MK571 (resp.), as demonstrated by decreased TC50 values (indoxyl sulfate: 2.0 ± 0.7 mM; kynurenic 
acid: 9.0 ± 3.0) compared to the TC50 values in the absence of inhibitors, though not significant (indoxyl sulfate: 
3.6 ± 0.6 mM; kynurenic acid: not applicable). To support the importance of the combined effort of in- and efflux 
transport pathways especially in indoxyl sulfate detoxification, parent ciPTEC models lacking OAT1 demon-
strated enhanced resistance against indoxyl sulfate in the presence of efflux pump inhibitors (TC50 3.0 ± 0.5 mM).
The bioengineered renal tubule shows a three dimensional, tight and differentiated epithelial 
monolayer. Further development of a biotechnological platform for the removal of protein-bound waste 
products requires an optimal three-dimensional configuration, as a two-dimensional system poorly predicts renal 
xenobiotic handling. We recently successfully developed a three-dimensional bioengineered tubule system27, 
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which we here optimized and determined monolayer integrity by analyzing paracellular diffusion prior to trans-
port experiments. The transepithelial barrier function was measured using a custom-made flow system and inulin 
as a leakage marker labeled with fluorescein isothiocyanate (FITC), allowing live imaging of hollow fiber mem-
branes (HFM). Differentiated ciPTEC-OAT1 on double-coated HFM were compared to unseeded coated HFM 
(Fig. 3a). Within 1 min of perfusion, unseeded-HFM showed a sustained leakage compared to the fully PTEC 
covered HFM (Fig. 3b,c, no cells: 89 ± 4% vs. cells: 10 ± 3%; p < 0.001). This effect remained stable until the end 
of the perfusion experiment, thereby confirming the formation of a three-dimensional, efficient and stable tran-
sepithelial barrier by ciPTEC-OAT1 on HFM. To further elucidate polarization characteristics of ciPTEC-OAT1 
monolayers when cultured in a 3-dimensional (3D) HFM environment, the barrier function was also evaluated 
in 2D monolayers cultured on Transwell® filter inserts. When exposed to FITC-inulin, monolayers on inserts 
showed a limited barrier function of 20 ± 4% (p = 0.08) compared to unseeded filters (Fig. S1), confirming poor 
monolayer formation of ciPTEC-OAT1 using 2D systems in contrast to the 3D HFM environment. The presence 
of the tight junction protein ZO-1 along the boundaries of the cells (Fig. 3d) further endorsed the epithelial char-
acter of a homogenous and polarized cell monolayer on HFM. In addition to monolayer polarization, the expres-
sion of OAT1, BCRP and MRP4 in ciPTEC was compared between 2D and 3D cultures. Interestingly, significantly 
Figure 1. Concentration-dependent inhibition of OAT1- and OAT3-mediated fluorescein uptake by 
anionic uremic toxins. (a–h) A concentration range of eight uremic toxins were exposed to matured ciPTEC-
OAT1 (•) and -OAT3 (o) in the presence of 1 μM fluorescein, a known OAT model substrate. The intracellular 
fluorescent signal was detected by measuring samples at excitation wavelength 485 nm and emission wavelength 
535 nm. Blank data were subtracted and data were normalized to control (absence of uremic toxin). Nonlinear 
regression analysis was performed using Graphpad Prism 5.02. Data are shown as mean ± S.E.M. of three 
independent experiments performed, at least, in duplicate.
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increased expression levels of OAT1 were observed (Fig. 3e) as compared to flat monolayers and a trend towards 
an increase in BCRP and MRP4 (Fig. 3f,g) was shown, respectively. These data assume that a 3D environment 
induces membrane transporter expression, which might be the result of an improved epithelial character in 3D.
Bioengineered renal tubules show organic anion transport activity. To study the activity of OAT1, 
BCRP and MRP4 in the bioengineered renal tubules, we used the substrate fluorescein and life confocal imaging 
(Fig. 4a,b). Perfusion of the tubes with fluorescein solely (I) resulted in an in intracellular fluorescent signal, 
which increased significantly in the presence of efflux pumps inhibitors (II). In the presence of indoxyl sulfate 
(III) and kynurenic acid (IV), the fluorescein uptake was inhibited resulting in a less intense intracellular fluo-
rescent signal. In the final condition (V), fluorescein uptake was studied in the presence of probenecid, a blocker 
of OAT1, which resulted in a strongly diminished uptake. Semi-quantification of the normalized time-lapse 
experiment is presented in Fig. 4c. For statistical analysis, maximum uptake (Vmax) values were calculated from 
Uremic toxin
Cm (μM)  
in ESRD patients1
ciPTEC-OAT1 
(IC50 - μM) R square
ciPTEC-OAT3 
(IC50 - μM) R square
Indoxyl sulfate 110 25 ± 4 0.92 83 ± 41 0.42
l-Kynurenine 6 65 ± 8 0.92 219 ± 66 0.54
Kynurenic acid 1 6 ± 1 0.95 6 ± 1 0.83
Indole-3-acetic acid 4 19 ± 2 0.93 148 ± 60 0.49
Hippuric acid 398 5 ± 1 0.95 22 ± 9 0.78
Indoxyl-β-glucuronide 9 492 ± 68 0.67 527 ± 218 0.55
p-Cresylglucuronide 44 2650 ± 922 0.28 588 ± 81 0.36
p-Cresylsulfate 675 79 ± 14 0.84 112 ± 19 0.80
Table 1.  Uremic toxins inhibit OAT1- and OAT3-mediated fluorescein uptake. The eight tested anionic 
uremic toxins inhibit OAT1- and OAT3-mediated fluorescein uptake in a concentration-dependent manner. 
Mean plasma levels of uremic toxins in ESRD patients were extracted from Duranton et al.6. R square: goodness 
of fit values extracted from non-linear regression analysis.
Figure 2. Handling of indoxyl sulfate and kynurenic acid by OAT1, BCRP and MRP4 in flat monolayers. 
In matured ciPTEC-OAT1, a concentration-dependent uptake of (a) IS and (b) KA (white) was shown using 
LC-MS/MS analysis of the uremic toxins. In the presence of probenecid (P, grey), the uptake of both toxins 
was attenuated. Moreover, the IS uptake was inhibited in the presence of KA (100 μM; black), and vice versa. 
The role of BCRP and MRP4 in the efflux of IS and KA was shown using an MTT assay. The experiment was 
performed in the absence (•) or presence (◦) of efflux pump inhibitors (KO143 (10 μM) and MK571 (5 μM)). 
Nonlinear regression analysis was performed using Graphpad Prism 5.02. Data are shown as mean ± S.E.M. of 
three independent experiments performed in triplicate. *p < 0.05, ***p < 0.001 using one-way ANOVA analysis 
followed by Dunnett’s multiple comparison test.
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background corrected arbitrary fluorescence units (AFU) data (Fig. 4d). A significant increased fluorescein 
uptake was detected when studied in the presence of efflux pumps inhibitors (208 ± 10%; p < 0.001). Again, this 
was inhibited by indoxyl sulfate (45 ± 13%; p < 0.001) and kynurenic acid (83 ± 3%; p < 0.001). In the presence of 
Figure 3. Bioengineered renal tubules show transepithelial barrier function and polarized characteristics. 
FITC-inulin leakage was measured in matured ciPTEC-OAT1 seeded on coated HFM. (a) Schematic 
presentation of the experimental set-up in the absence (upper panel) or presence (lower panel) of cells.  
(b) Representative eal-time images of the two different conditions are shown; unseeded (square) and seeded 
(circle) HFM. In the absence of cells, a bright green fluorescent signal was detected at the apical membrane, 
whereas in the presence of cells the signal was clearly attenuated. Representative real-time images of the two 
different conditions were shown. (c) Semi-quantification of FITC-inulin diffusion in the absence (square) and 
the presence of ciPTEC-OAT1 (circle) on HFM. Seeded HFM showed significantly less FITC-inulin leakage 
demonstrating monolayer tightness. From each single replicate 4 different regions in focus were analyzed.  
(d) The expression of ZO-1 (green) was demonstrated in a homogenous cell monolayer cultured on HFM. Scale 
bar: 10 μm. (e–g) The OAT1, BCRP and MRP4 mRNA expression levels were investigated in matured ciPTEC-
OAT1 cultured in well plates and on HFM. Gene expression levels were normalized to expression levels of the 
reference gene GADPH (h) and were expressed as fold increase when cultured on HFM (black) compared 
to matured cells in well plates (white). Data are shown as mean ± S.E.M. of three independent experiments 
performed, at least, in duplicate. ***p < 0.001, using an unpaired t test.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:26715 | DOI: 10.1038/srep26715
probenecid, fluorescein uptake was clearly attenuated as well (96 ± 3%; p < 0.001). These findings are compatible 
with the formation of a functionally active bioengineered renal tubule.
Bioengineered renal tubules facilitate uremic toxin secretion despite protein binding. Lastly, 
we investigated the capability of the bioengineered renal tubules to actively secrete protein bound uremic toxins. 
Active clearance of indoxyl sulfate and kynurenic acid in the absence of human serum albumin was studied by 
perfusing the tubules with 100 μM of the uremic toxin and measuring transport into the apical compartment. This 
revealed a clearance of 44 ± 6 μl.min−1.cm−2 and 72 ± 20 μl.min−1.cm−2 for indoxyl sulfate and kynurenic acid, 
respectively. This secretion was attenuated by probenecid (by 55 ± 6, p < 0.05 and 71 ± 7%, respectively) and by 
the efflux pumps inhibitors (68 ± 5, p < 0.001; 68 ± 6%, respectively), indicating active transepithelial transport 
of both uremic solutes across the epithelial cell monolayer. In a separate experiment we observed that clearance 
of the uremic toxins was fully restored after the probenecid treatment, when the bioengineered tubules were 
re-perfused with the toxins (data not shown). These findings confirmed that the cell monolayer is still viable after 
multiple treatments, including probenecid incubation, and that probenecid has an inhibitory effect on transport 
protein level solely. To further mimic the physiological situation, the ability of the bioengineered tubules to facil-
itate protein-bound toxin transport was shown. In this setup, we achieved a protein binding of indoxyl sulfate 
slightly lower than previously reported (73 ± 3%)28 in the presence of 1 mM HSA. Under the same conditions, 
kynurenic acid showed a protein binding of 63 ± 5%. Interestingly, the clearance of protein-bound indoxyl sul-
fate (74 ± 10 μl.min−1.cm−2, p < 0.01) and kynurenic acid (101 ± 23 μl.min−1.cm−2, ns) was enhanced when com-
pared to the clearance of both toxins in the absence of albumin. Again, transport was attenuated by probenecid 
(99.4 ± 0.2, p < 0.001; 49 ± 15%, respectively) and by the efflux pumps inhibitors (98.9 ± 0.2, p < 0.001; 58 ± 14%, 
respectively). These findings suggest that protein binding positively affects the renal tubular clearance of the 
uremic toxins.
To study the mechanism of protein bound uremic toxin handling further, we not only performed a basolateral 
perfusion with FITC-bovine serum albumin (BSA-FITC), but also studied the uptake of BSA-FITC from the api-
cal site. Wilmer and Jansen et al. previously reported on the presence of a megalin-mediated albumin reabsorp-
tion mechanism in ciPTEC, located at the PTEC apical membrane21,22. Figure 5e–g shows BSA-FITC uptake in 
renal tubules after basolateral or apical exposures. Upon basolateral perfusion, intracellular BSA-FITC could not 
Figure 4. OAT1-mediated fluorescein uptake in bioengineered renal tubules. Fluorescein was used as a 
model substrate in an advanced fiber perfusion system. (a) Schematic presentation of the experimental set-up: I. 
Fluorescein perfusion, II. Fluorescein perfusion in the presence of efflux pump inhibitors (EP; (5 μM)),  
III and IV. Fluorescein perfusion in the presence of efflux pump inhibitors and indoxyl sulfate (III; 100 μM)  
or kynurenic acid (IV; 30 μM), V. Fluorescein perfusion in the presence of probenecid (P; 100 μM).  
(b) Representative real-time images of the five different conditions. Scale bare: 10 μm. (c) Semi-quantification 
of fluorescein uptake data in the absence or presence of the efflux pumps inhibitors solely, in combination 
with IS and KA, and in the presence of probenecid. From each single replicate 4 different regions in focus were 
analyzed. Data were fitted according to one-site total binding saturation curve using non-linear regression 
analysis. (d) Vmax values from all conditions were calculated from the corrected AFU data according to 
michaelis-menten kinetics using non-linear regression analysis. For statistical analysis, the Vmax values 
obtained from condition EP and P where compared to only fluorescein uptake (F). Conditions IS + EP and  
KA + EP were compared to EP. Data are shown as mean ± S.E.M. of three independent experiments performed 
in duplicate. ***p < 0.001, using one-way ANOVA followed by Dunnett’s multiple comparison test.
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Figure 5. Transepithelial clearance of indoxyl sulfate and kynurenic acid in the presence of human serum 
albumin, and albumin-FITC handling in bioengineered renal tubules. (a–d) Transepithelial clearance 
of indoxyl sulfate and kynurenic acid. Schematic presentation of the experimental set up of IS and KA 
transepithelial transport in the absence (a) or presence (b) of HSA is reported. Quantification of IS (c) and KA 
(d) clearance in the absence (−) or presence (+) of HSA. The protein bound fraction of IS was 73 ± 5% and 
63 ± 8% of KA was bound to albumin. Data are shown as mean ± S.E.M. of three independent experiments 
performed in duplicate. *p < 0.05, **p < 0.01 compared to IS in the absence of HSA, ###p < 0.001 compared to IS 
in the presence of HSA. Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple 
comparison test. (e–g) Endocytosis-mediated albumin uptake in bioengineered renal tubules. Cellular BSA-
FITC uptake (green) in renal tubules (nuclei: blue) after 30 min exposure from the (e) basolateral compartment 
at 37 °C (f ) apical compartment at 37 °C and (g) apical compartment at 4 °C. Active uptake was detected solely 
when BSA-FITC uptake was performed at 37 °C, as indicated by the red arrows. (h) Collagen IV expression 
(green) in renal tubules showed a highly similar pattern as BSA-FITC uptake as shown in b. Scale bare: 10 μm.
www.nature.com/scientificreports/
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be detected (Fig. 5e). This observation is in agreement with the retention of albumin in the blood compartment 
under physiological conditions to prevent protein loss29. Figure 5f shows that active uptake of BSA-FITC was 
detectable when exposed to the apical compartment at 37 °C, thereby confirming that reabsorption is functional 
in renal tubules (red arrows). Importantly, this uptake was highly reduced when apical exposure took place at 4 °C 
(Fig. 5g), thereby further confirming the presence of an active endocytosis process in the bioengineered kidney 
tubules. Note that the BSA-FITC reabsorbed at 37 °C binds to collagens present in the tubules27. As described 
by Rueth et al., albumin is known to bind hydrophobic compounds like collagen30. Concurrently, the pattern 
observed in ciPTEC upon BSA-FITC reabsorption indeed showed high similarities to the pattern observed when 
stained against collagen IV (Fig. 5h). As a consequence, the typical endocytosis BSA-FITC particles, which are 
usually detected in this reabsorption mechanism, are less clear in this setting. Nevertheless, these data show that 
albumin is actively reabsorbed by the apical membrane and not transported along with uremic toxins from the 
basal compartment across renal tubules.
Discussion
The renal clearance of organic anions, including protein bound endogenous metabolites, highly depends on active 
secretion, which is confined to the tubular system. In ESRD, this function is severely compromised resulting in 
the accumulation of these metabolites in patients. Current dialysis therapies insufficiently remove the protein 
bound uremic toxins, which contributes to the high morbidity and mortality rates of the disease31, therefore, 
alternative treatment strategies are warranted. In this study, a bioengineered renal tubule was successfully devel-
oped and transepithelial transport of albumin-bound uremic toxins was demonstrated. Key in this process is the 
concerted action between (basolateral) uptake and (apical) efflux performed by transporters with designated 
membrane localization. In exchange for intracellular α-ketoglutarate, the OATs efficiently translocate organic 
anions from the blood compartment into the intracellular space against an electrochemical gradient. The efflux 
pumps belonging to the ABC family of transmembrane transporters then couple ATP hydrolysis to their urinary 
excretion in a unidirectional fashion. Using a unique, robust and complete human cell model, we first identified 
eight anionic uremic toxins for their interaction with OAT1- and OAT3-mediated transport in flat cell monolay-
ers. Next, the essential role of the ABC transporters BCRP and MRP4 in cellular detoxification through efflux was 
demonstrated. Finally, a three-dimensional bioengineered tubule containing a polarized cell monolayer with a 
clear epithelial barrier function was developed. These human bioengineered tubules demonstrated active clear-
ance of albumin-bound anionic uremic toxins as a next step in BAK engineering. Note that the formation of a 
cellular barrier is not unique for ciPTEC but also found for intestinal epithelial cells when cultured on HFM (data 
not shown).
The concept of BAK engineering was initiated in the late 80’s of last century by Aebischer et al. with 
non-human cell models (i.e. the canine derived MDCK or pig originating LLC-PK1 cells) cultured on HFM32. 
Follow-up studies by Humes and co-workers used cells of human origin, but with a major focus on the immu-
nomodulatory effects for treatment of critically ill patients suffering from acute kidney injury33–35. Phase I and II 
clinical trials showed reduced cytokine levels and long-term survival improvement compared to the non-treated 
group. However, a follow-up clinical phase IIb trial failed due to difficulties in the manufacturing process of the 
BAK and the clinical study design36. One of the challenges to successfully develop a BAK is a suitable cell source to 
replace transport functions of the kidneys34,37. Primary renal epithelial cells show a high batch-to-batch variability 
in quality and function and dedifferentiation upon prolonged cultivation, and therefore hamper reproducibility. 
Moreover, to obtain a sufficient number of primary renal epithelial cells for a BAK approach is another hurdle 
to overcome37. Recent advances in the application of stem cells (i.e. of embryonic origin or induced pluripotent 
cells) into a PTEC-like phenotype is a promising alternative38–40, but this has not been characterized sufficiently 
nor their capability to maintain the OATs in culture has been proven. Human renal cells loose the expression of 
these essential transport proteins and (in part) their proximal tubular phenotype upon culturing21,41. This phe-
nomenon has already been described in 199042 and has, as of yet, not been solved, however, stable expression of 
OATs in renal cell lines is a prerequisite for renal functional replacement therapies as emphasized in a BAK. Here, 
we applied a recently optimized, robust and translational human renal cell model that endogenously expresses 
a panel of renal xenobiotic transporters successfully complemented with the OATs21–23. This appeared to be an 
asset, as we demonstrated for the first time active renal tubular secretion of the protein-bound uremic toxins 
indoxyl sulfate and kynurenic acid.
Using a conventional two-dimensional approach, the potency of eight uremic toxins to inhibit basolateral 
OAT1 and −3 mediated transport at clinically relevant concentrations was demonstrated6,20. The inhibitory 
potencies are in good agreement with previously published data obtained in animal models or in transfected cell 
systems expressing OAT1 or OAT318,20. We selected two uremic toxins because of the highest inhibitory potency 
(kynurenic acid, this study) and widely described associations with uremic syndrome complications (indoxyl 
sulfate)8,11. Indoxyl sulfate has been considered to be a causative factor in CRF progression43, with most likely 
a dominant role of hOAT1 as its affinity for this transporter is at least 3-fold higher as compared to OAT3 (this 
study and18). Parent ciPTEC, lacking OAT1, were more resistant against indoxyl sulfate, but in ciPTEC-OAT1 a 
concentration-dependent reduction in cell viability was found. This effect was amplified when inhibitors of the 
efflux transporters, BCRP and MRP4, were applied, confirming the concerted action of uptake and efflux trans-
porters in uremic toxin handling. Kynurenic acid showed a lower intrinsic toxicity as compared to indoxyl sulfate, 
despite its higher affinity for OAT1 (this study), BCRP and MRP414. The molecular mechanisms through which 
both uremic toxins exert their cytotoxic potential are largely unrevealed.
The high affinity of kynurenic acid for OAT1, BCRP and MRP4 was demonstrated further by the higher 
bioengineered renal tubular clearance as compared to the elimination of indoxyl sulfate, either in the presence 
or absence of albumin. Moreover, it was shown that albumin itself is not taken up by ciPTEC from the baso-
lateral site, but actively reabsorbed from the apical compartment. Interestingly, in the presence of albumin the 
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transport of indoxyl sulfate and kynurenic acid was enhanced, which emphasizes the ability of ciPTEC to shift 
the protein-binding and allow for active secretion of the free fraction. These data support that albumin may stim-
ulate transport of organic anions, as was suggested earlier in the 80’s of last century by Besseghir and Depner et 
al. They showed that albumin facilitated para-aminohippurate uptake in isolated rabbit proximal tubules and rat 
kidney slices44,45. Moreover, Pichette et al. demonstrated altered dynamics of furosemide in hypoalbuminaemic 
rabbits46,47. Furosemide is a known diuretic agent, and organic anion, which targets the Na+-K+-Cl− 
cotransporter-2 (NKCC2) located downstream the proximal segment in the apical membrane of the thick 
ascending limb of Henle’s loop. Furosemide is highly protein bound (approx. 98%46,) and actively secreted via 
the proximal tubules into the apical compartment. In hypoalbuminaemic rabbits, higher furosemide doses were 
required to achieve a similar diuretic effect as in control rabbits46, supporting the important role of albumin in 
facilitating active transport of the organic anion. This may be the result of electronegative to -neutral transition 
of the compounds when bound to albumin and/or post-translational modifications of albumin when toxins are 
bound48,49. The tertiary structure of albumin may also stimulate the binding and transport of metabolites across 
the capillary wall into the interstitial compartments. As shown recently, the binding capacity of albumin was 
demonstrated to be diminished in CRF patients, most likely due to post-translational guanidylation of albumin 
sites30. The attenuated albumin binding capacity in CRF patients will probably contribute to less efficient trans-
port of uremic toxins by PTEC, thus resulting in elevated plasma levels and their known consequences. Note that 
the double-coated HFM used in our bioengineered renal tubules allow albumin to reach the target transporters, 
emphasizing further the potential of the device in BAK applications. Future research should elucidate the impact 
of modified albumin as observed in uremic patients in the removal of uremic toxins using a BAK platform.
Altogether, a successful bioartifical renal tubule was established which presented a clear barrier function and 
facilitated transepithelial transport of protein-bound indoxyl sulfate and kynurenic acid. This provides an inno-
vative basis for regenerative nephrology through advanced function replacement and paves the way to progress 
towards potential clinical applications focusing at: i) optimization and up-scaling of the system with the aim of 
maintaining the best possible cell function under sterile conditions for extended time periods; ii) in vitro vali-
dation of the bioreactor with respect to uremic toxin kinetics; iii) the safety aspects as ciPTEC are classified as 
GMO’s, for which thorough research in agreement with European guidelines for advanced therapy medicinal 
products (European Medicines Agency) is needed to enable the applications of GMO in medicinal products50; 
iv) preclinical validation of the model, and v) prediction of uremic toxin clearance by the bioengineered system in 
clinical settings, for which research should be directed at building a physiologically-based computational model. 
This allows predicting the capacity needed for treatment of uremia and defining the most suitable application 
strategies in function of solute kinetics. Hence, such model would not only apply to uremia treatment, but can be 
used for mimicking 3D scenarios of kidney disease modeling as well as for drug- toxicity and - efficacy testing.
Methods
Chemicals and cell culture materials. Chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The 
Netherlands) unless stated otherwise. The uremic toxins p-cresylsulfate and p-cresylglucuronide were synthesized 
by the Institute for Molecules and Materials, Radboud University, Nijmegen, The Netherlands. MicroPES type 
TF10 hollow fiber capillary membranes (wall thickness 100 μm, inner diameter 300 μm, max pore size 0.5 μm) 
were obtained from Membrana GmbH (Wuppertal, Germany). Cell culture plates were purchased from Greiner 
Bio-One (Monroe, NC).
Cell culture of ciPTEC-OAT1 and -OAT3. The transduction of OAT1 and OAT3 in ciPTEC22 was per-
formed as previously described by Nieskens et al.23 and cells were cultured in supplemented PTEC culture media 
as described by Jansen et al.21. Fibers were coated and seeded as described by Jansen et al.27.
Fluorescein inhibition assay. The potency of a panel of eight anionic uremic toxins to inhibit OAT1- and 
OAT3-mediated fluorescein uptake was investigated in flat monolayers using an inhibition assay as previously 
described by Nieskens et al.23. Blank fluorescence data were subtracted and relative data compared to control 
were plotted.
Uptake of indoxyl sulfate and kynurenic acid by ciPTEC-OAT1. In short, active OAT1-mediated 
uptake of indoxyl sulfate and kynurenic acid was investigated using two concentrations of toxins (3 and 30 μM) 
in the presence or absence of probenecid (100 μM), kynurenic acid (100 μM) or indoxyl sulfate (100 μM). 
Intracellular toxin concentrations were analyzed using a LC-MS/MS system (Thermo scientific, Breda, The 
Netherlands) following the method described by Mutsaers et al.14. Data processing was performed using the 
Thermo Xcaliber software (Thermo scientific, version 2.1) and absolute data were plotted.
Cell viability assay. An MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell prolifer-
ation assay was performed as previously described by Nieskens et al.23. Background values were subtracted and 
normalized data were plotted.
Monolayer polarization and transepithelial barrier function. To investigate the barrier function of 
matured ciPTEC-OAT1 cultured on HFM, fibers were perfused with FITC-inulin (0.1 mg/ml in Krebs-Henseleit 
buffer supplemented with 10 mM Hepes (KHH, pH 7.4)) and diffusion was measured in real-time. From each 
single replicate 4 different regions in focus were analyzed. Semi-quantification of real-time data was performed 
using Image J software (version 1.40 g) and normalized data were plotted. To determine the polarization of the 
ciPTEC-OAT1 monolayer on HFM, the expression of tight junction protein zonula occludens-1 (ZO-1) was 
investigated according to the protocol as previously described by Jansen et al.27.
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Detection of OAT1, BCRP and MRP4 mRNA expression. The mRNA expression of OAT1, BCRP and 
MRP4 was examined in ciPTEC-OAT1 when cultured in flat monolayers and as bioartificial renal tubules as pre-
viously described by Jansen et al.21. Gene expression levels were normalized to expression levels of the reference 
gene GADPH and were expressed as fold increase compared to matured cells in well plates.
Fluorescein assay. To determine the OAT1 as well as BCRP and MPR4 transport activity in matured 
ciPTEC-OAT1 cultured on HFM, the fibers were connected to a similar perfusion set-up as was used for the bar-
rier function assay. To measure active fluorescein uptake in real-time, fibers were perfused using 1 μM fluorescein 
in KHH in the presence or absence of specific drug transporter inhibitors or uremic toxins. Background corrected 
data were normalized against fluorescein uptake in the absence of inhibitors and were fitted according to one-site 
total binding saturation curve using non-linear regression analysis. In addition, Vmax values (i.e. the maximum 
initial rate of a reaction) were calculated from the corrected AFU data according to Michaelis-Menten kinetics 
using non-linear regression analysis.
Transepithelial transport of indoxyl sulfate and kynurenic acid. Transepithelial transport of indoxyl 
sulfate and kynurenic acid through the HFM with matured ciPTEC was studied using a similar perfusion set-up 
as was used for the barrier function assay. First, fibers were pre-incubated using efflux pump EP inhibitors (5 μM) 
or probenecid (100 μM) for 15 min. Next, the fibers were perfused using 100 μM IS or 30 μM KA in the presence 
or absence of inhibitors for 10 min and samples from the apical compartment were collected (100 μl). To deter-
mine the ability of ciPTEC to initiate a shift from the toxin protein-bound fraction to a free fraction for trans-
port, similar conditions were investigated in the presence of human serum albumin ((HSA), 1mM). The binding 
efficiency of IS and KA to HSA was determined an ultrafiltration technique with a 30 kDA cut-off filter (Merck 
Millipore, Amsterdam, the Netherlands). The mixture was centrifuged for 15 min at 6,500 × rcf at rT and the 
ultrafiltrate containing the free toxin fraction was collected. The percentage albumin-bound (Cbound) of indoxyl 
sulfate and kynurenic acid was calculated according to equation 1:
= − ⁎C [(C C )/C ] 100 (1)bound total free total
where Ctotal is the total concentration of toxin solution and Cfree the free toxin concentration present in ultrafil-
trate, both in μmol/l. All samples collected from the binding analysis and the apical compartment after the trans-
port experiment were analyzed using a LC-MS/MS system as described earlier.
In vitro clearance values of the transepithelial transport of both toxins were calculated according to equation 2:
= ⁎Cl (U V)/P (2)
where U is the apical concentration in μmol/ml, V the volume in the apical compartment in ml and P the baso-
lateral concentration in μmol/ml.
Next, the in vitro clearance was calculated according to equation 3:
=Cl (Cl/T)/A (3)invitro
where Cl is the calculated clearance, T is the time in min and A the surface of the fiber in cm2.
All toxin samples were analyzed using a LC-MS/MS system as described earlier in this section.
Endocytosis-mediated albumin uptake in bioengineered renal tubules. Matured renal tubules 
were assembled in our custom-made flow system and perfused with BSA-FITC (25 μg/ml) for 30 min at 
37 °C. In the next condition, fibers were perfused with KHH buffer and BSA-FITC (25 μg/ml) was added api-
cally and exposed for 30 min at 37 °C. As a control, the apical exposure was also performed at 4 °C in order to 
inhibit endocytosis. After the uptake was arrested, tubules were fixed using 2% (w/v) PFA for 5 min at room 
temperature. Finally, tubules were mounted using Prolong Gold Antifade Reagent with DAPI (Cell Signaling 
Technology, Leiden, The Netherlands) and BSA-FITC localization in the cells was examined using the Leica 
SPE-II – DM14000 (Leica Microsystems, Rijswijk, The Netherlands) and images were captured using the Leica 
Microsystems LAS-AF software version 1.00.71.
Data analysis. All data are expressed as mean ± S.E.M of multiple replicates. Inhibition data were fitted 
according to one-site total binding saturation curve using non-linear regression analysis and Vmax values were 
calculated according to Michaelis-Menten kinetics using non-linear regression analysis. Statistical analysis was 
performed using one-way ANOVA analysis followed by Dunnett’s or Tukey’s multiple comparison test, or, when 
appropriate, an unpaired t test with GraphPad Prism version 5.02 (La Jolla, CA). A p-value of <0.05 was consid-
ered significant.
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